COVID-19

New study results show that of those who tested or were presumed positive for SARS-CoV-2, 44% developed neurological symptoms.

Investigators learned that the degree of response depended on whether an individual has had 1, 2, 3, or 4, exposures through infection, vaccination, or both.

Some study limitations include that follow-up data were missing for some patients who dropped out of the study during the follow-up stages and the timing of the follow-up echocardiograms were random and driven by preference versus standard protocol.

The kit helps detect SARS-CoV-2 RNA in nasopharyngeal, anterior nasal, mid-turbinate nasal or oropharyngeal swab specimens from individuals suspected of COVID-19 by their health care provider.

Both data sets confirm previously announced results showing that the boost protects against the variant.

Investigators say that the post-acute sequalae markers are Epstein-Barr virus (EBV) DNA levels in the blood, pre-existing types 2 diabetes, the presence of certain antibodies, and SARS-CoV-2 RNA levels in the blood.

Investigators analyzed data to determine the outcomes and risk factors for severe cases and how individuals with inflammatory bowel disease are affected.

New study results show that there are more incidences of this inflammation of the heart muscle related to not being vaccinated than there are to the vaccine itself.

Having such a program spearheaded by pharmacists has helped show the public the vital roles that pharmacists play.

The FDA also expanded the pediatric emergency use authorization for remdesivir to include the treatment of non-hospitalized pediatric patients at high risk of disease progression.

This recent research also found that those who received the Moderna vaccine were less likely to be hospitalized compared to recipients of the Pfizer-BioNTech vaccine.

Stanford Medicine investigators were able to estimate who is most likely to land in the hospital.

Results of an analysis show that 3 doses of either Oxford/AstraZeneca COVID-19 or Pfizer BioNTech COVID-19 neutralizes the variant.

Further, the Index is based on proprietary data from PCR testing services administered by Walgreens.

Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discussed what the impact of the pandemic has been on the advancement of data interoperability in health care.

A sizable number of clinical trial participants say they had at least 1 AE, with fatigue and headaches the most common.

The analysis describes cost-effective options for individuals without symptoms and recommends isolation strategies to help policymakers safeguard against resurgences.

Patients can sometimes develop Guillain-Barre syndrome after having a recent respiratory illness or digestive tract infection and, in rare cases, after receiving certain vaccines.

Donald Alcendor, PhD, and Angela Rasmussen, PhD, explain how to discuss the importance of COVID-19 booster shots with patients.

Jeff Goad, PharmD, MPH, and Angela Rasmussen, PhD review the population trends of COVID-19 booster shots.

The Biden administration announced that it would make 400 million nonsurgical N95 masks for US citizens available free of charge at community health centers and retail pharmacies across the United States.

Results from multiple studies show that the effectiveness of nirmatrelvir, the active main protease inhibitor of Paxlovid is maintained.

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Ending the COVID-19 pandemic requires an understanding of how to manage the inflammatory dysfunction that the virus causes.

Study results show health plans paid most of the drug costs, despite the lack of effect seen on COVID-19.